Oxford
BioDynamics
("OBD" or the
"Company" and, together
with its subsidiaries, the "Group")
Response to Share Price
Movement
Oxford, UK - 3 December
2024 - Oxford BioDynamics,
Plc (AIM: OBD, the Company), a precision
clinical diagnostics company bringing specific and sensitive tests
to the practice of medicine based on OBD's EpiSwitch® 3D genomics platform notes the recent movement in
the share price. As per the announcement issued on 14 October 2024,
the Company is continuing to explore a number of different options
to bring additional near-term funding into the business. The Board
is mindful that market conditions remain challenging and therefore
there is no guarantee of a successful conclusion. As previously
announced the Company will require additional cash resources by
early Q1 of 2025. The Board will provide further updates as
appropriate.
-Ends-
For
more information:
|
Oxford BioDynamics
Plc
Jon
Burrows, CEO
Paul
Stockdale, CFO
|
+44
(0)1865 518910
|
|
Shore Capital
(Nominated Adviser and Broker to OBD)
Stephane
Auton
Lucy
Bowden
|
+44 (0)20
7408 4090
|
|
WG Partners
(Joint Broker to
OBD)
David
Wilson / Claes Spång /
Satheesh Nadarajah / Erland Sternby
|
+44
(0)20 3705 9330
|
|
Vigo
Consulting
(Media / Analyst enquiries
for OBD)
Rozi Morris
|
+44 (0)20
7390 0230
obd@vigoconsulting.com
|
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) is
an international biotechnology company, advancing personalized
healthcare by developing and commercializing precision clinical
diagnostic tests for life-changing diseases.
Currently OBD has two commercially available products:
the
EpiSwitch® PSE (EpiSwitch
Prostate Screening test) and
EpiSwitch® CiRT (Checkpoint
Inhibitor Response Test) blood tests. PSE boosts the predictive
accuracy of a PSA test from 55% to 94% when testing the presence or
absence of prostate cancer. CiRT is a
highly accurate (85%) predictive response test to immuno-oncology
checkpoint inhibitor treatments.
The tests are based on OBD's
proprietary 3D genomic biomarker platform, EpiSwitch® which enables screening, evaluation, validation and monitoring
of biomarkers to diagnose patients or determine how individuals
might respond to a disease or treatment.
OBD's clinical smart tests have the
potential to be used across a broader range of indications, and new
tests are being developed in the areas of oncology, neurology,
inflammation, hepatology and animal health.
The Group's headquarters and UK
laboratories are in Oxford, UK. Its US operations and clinical
laboratory are in Maryland, USA, along with a reference laboratory
in Penang, Malaysia.
OBD is listed on the London Stock
Exchange's AIM (LSE: OBD). For more information, please visit the
Company's website,
www.oxfordbiodynamics.com, X
(@OxBioDynamics) or
LinkedIn.